Journal
CLINICAL CANCER RESEARCH
Volume 19, Issue 14, Pages 3755-3763Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-3488
Keywords
-
Categories
Funding
- Damon Runyon Clinical Investigator Award [R01 AR056720, R03 MH095529]
- SPORE in Skin Cancer [P50 CA9368305]
- NIH/National Cancer Institute
- NIH/National Institute of Allergy and Infectious Diseases [R01 A1025082]
- Leukemia & Lymphoma Society
- German Research Foundation (DFG)
- Swiss National Science Foundation
- Fondation Rene Touraine
- [R01 AI097128]
- [R01 CA122569]
- [GU1271/2-1]
Ask authors/readers for more resources
Purpose: In leukemic cutaneous T-cell lymphoma (L-CTCL), malignant T cells accumulate in the blood and give rise to widespread skin inflammation. Patients have intense pruritus, increased immunoglobulin E (IgE), and decreased T-helper (T-H)-1 responses, and most die from infection. Depleting malignant T cells while preserving normal immunity is a clinical challenge. L-CTCL has been variably described as a malignancy of regulatory, T(H)2 and T(H)17 cells. Experimental Design: We analyzed phenotype and cytokine production in malignant and benign L-CTCL T cells, characterized the effects of malignant T cells on healthy T cells, and studied the immunomodulatory effects of treatment modalities in patients with L-CTCL. Results: Twelve out of 12 patients with L-CTCL overproduced T(H)2 cytokines. Remaining benign T cells were also strongly T(H)2 biased, suggesting a global T(H)2 skewing of the T-cell repertoire. Culture of benign T cells away from the malignant clone reduced T(H)2 and enhanced T(H)1 responses, but separate culture had no effect on malignant T cells. Coculture of healthy T cells with L-CTCL T cells reduced IFN gamma production and neutralizing antibodies to interleukin (IL)-4 and IL-13 restored T(H)1 responses. In patients, enhanced T(H)1 responses were observed following a variety of treatment modalities that reduced malignant T-cell burden. Conclusions: A global T(H)2 bias exists in both benign and malignant T cells in L-CTCL and may underlie the infectious susceptibility of patients. T(H)2 cytokines from malignant cells strongly inhibited T(H)1 responses. Our results suggest that therapies that inhibit T(H)2 cytokine activity, by virtue of their ability to improve T(H)1 responses, may have the potential to enhance both anticancer and antipathogen responses. (C) 2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available